Evaluating predictors of paclitaxel-associated peripheral neuropathy: a pharmacodynamic modelling approach
- In: Poster Presentation
- At: Stockholm (Sweden) (2017)
- Type: Poster
- Poster code: P-A-109-Monday
- By: WILLIAMS OJARA, Francis (Freie Universitaet Berlin, Germany, Clinical Pharmacy & Biochemistry, Institute of Pharmacy, Berlin, Germany)
- Co-author(s): Francis Williams Ojara: Clinical Pharmacy & Biochemistry, Institute of Pharmacy, Freie Universitaet Berlin, Germany, Berlin, Germany
Andrea Henrich: Clinical Pharmacy & Biochemistry, Institute of Pharmacy, Freie Universitaet Berlin, Germany, Berlin, Germany
Markus Joerger : Medical Oncology and Hematology, Cantonal Hospital, St Gallen, Switzerland
Charlotte Kloft : Clinical Pharmacy & Biochemistry, Institute of Pharmacy, Freie Universitaet Berlin, Germany, Berlin, Germany - Abstract:
Backgrounds
Peripheral neuropathy (PN) is a dose limiting, cumulative adverse event of paclitaxel (PTX) with relevant negative impact on patient’s quality of life (QoL). PTX dose and exposure (time above a threshold plasma concentration of 0.05 μM, TC>0.05) are known predictors of PN from standard statistical tests with a single severity grade per.. The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress.
Please login
Last update 28 September 2023